Who is Namita Thapar and how is she related to IPO-bound Emcure Pharma?

Shark Tank fame and Emcure Pharmaceuticals Executive Director Namita Thapar will offload her stake partially in the company's initial public offering (IPO), which will launch next week.

She holds 63,39,800 equity shares as a key promoter of Emcure Pharma, representing a 3.5% stake, as per a communique issued by the company earlier this month.

According to the advertisement by the company announcing the IPO, Namita's weighted average cost of acquisition (WACA) of her stake is ₹3.44 per share. Since she holds 63,39,800 shares in the company, the cumulative WACA of her stake stands at ₹2.18 crore.

The company is offering its shares at a price range of ₹960 to ₹1,008 each. According to Business Today, if the shares are sold at the highest price of ₹1,008, she will earn an incredible return of 29,300% or 293 times the original investment from the offer-for-sale portion.

Who is Namita Thapar?

Namita Thapar is a prominent Indian entrepreneur, business executive, and angel investor. Born on March 21, 1977, she is the Executive Director of Emcure Pharma, a company founded by her father, Satish Ramanlal Mehta. She has played a crucial role in the company's growth.

A popular figure in the investment world, Namta has invested in over 100 companies that featured on Shark Tank India, a business reality television series.

She completed an MBA from Duke University's Fuqua School of Business in 2001 and is a Chartered Accountant from ICAI. After relocating to India, she initially served as chief financial officer (CFO) at Emcure Pharmaceuticals and subsequently rose to the position of executive director.

Namita has been in the news recently because her company, Emcure Pharmaceuticals, is about to go public, creating a lot of buzz in the market.

Namita is likely to shed a partial stake from her shares in the company in the upcoming IPO, as part of the offer-for-sale (OFS) component.

About Emcure Pharmaceuticals IPO

The Emcure Pharma IPO is a mainboard IPO offering of ₹1,952.03 crore, open for subscription from July 3, 2024, to July 5, 2024. It includes a fresh issue of ₹800 crore and an offer for sale worth ₹1,152.03 crore.

Emcure Pharmaceuticals Limited, established in April 1981, develops, manufactures, and sells a variety of pharmaceutical products worldwide in several important therapeutic areas.